Novel Acylguanidine Derivatives Targeting Smoothened Induce Antiproliferative and Pro-Apoptotic Effects in Chronic Myeloid Leukemia Cells.
The most relevant therapeutic approaches to treat CML rely on the administration of tyrosine kinase inhibitors (TKIs) like Imatinib, which are able to counteract the activity of Bcr-Abl protein increasing patient's life expectancy and survival. Unfortunately, there are some issues TKIs are not...
Main Authors: | Alessandra Chiarenza, Fabrizio Manetti, Elena Petricci, Martial Ruat, Antonella Naldini, Maurizio Taddei, Fabio Carraro |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4774938?pdf=render |
Similar Items
-
Targeting the Oncoprotein Smoothened by Small Molecules: Focus on Novel Acylguanidine Derivatives as Potent Smoothened Inhibitors
by: Silvia Pietrobono, et al.
Published: (2018-12-01) -
Amino Acylguanidines as Bioinspired Catalysts for the Asymmetric Aldol Reaction
by: Ciril Jimeno
Published: (2021-02-01) -
Targeted Killing of Monocytes/Macrophages and Myeloid Leukemia Cells with Pro-Apoptotic Peptides
by: Mouldy Sioud, et al.
Published: (2019-07-01) -
Synthesis of Saccharumoside-B analogue with potential of antiproliferative and pro-apoptotic activities
by: Srinuvasarao Rayavarapu, et al.
Published: (2017-08-01) -
Antiproliferative and pro-apoptotic effects afforded by novel Src-kinase inhibitors in human neuroblastoma cells
by: Angelucci Adriano, et al.
Published: (2010-11-01)